Mutation of the adenomatous polyposis coli (APC) gene and the subsequent dysregulation of b-catenin are welldocumented abnormalities in familial adenomatous polyposis (FAP), as well as sporadic polyposis. Intriguingly, overexpression of the integrin-linked kinase (ILK) has been shown to modulate b-catenin subcellular localization and function. However, the signi®cance of this ®nding for human carcinogenesis remains unclear. Here, we report the increased biochemical activity and expression of ILK protein in polyps from FAP patients. Furthermore, dramatic increases in ILK immunoreactivity were observed in all abnormal crypts from sporadic polyps, when compared with the normal appearing crypts within the same resected specimens. As sulindac and aspirin are the two most important therapeutic/chemopreventative agents demonstrated in colorectal carcinogenesis, in both humans and animals, further investigation revealed that these non-steroidal antiin¯ammatory drugs (NSAIDs) target ILK and ILKmediated events in vivo. These include inhibition of, both the biochemical activation of ILK, inhibition of serine 9 GSK3b phosphorylation and the enhancement of TCF-4 transcriptional activity. In conclusion, ILK protein hyperexpression appears to be an early event in colonic polyposis. Additionally, ILK signaling is shown to undergo modulation by sulindac (and aspirin) for the ®rst time, indicating that it is likely to be one of the targets aected by these agents in vivo. Oncogene (2001) 20, 6250 ± 6257.
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non-steroidal anti-in¯ammatory drugs (NSAIDs); adenomatous polyposis coli (APC); bcatenin Mutations of the adenomatous polyposis coli (APC) gene are associated with the development of adenomas that are precursors to colorectal cancer (CRC) in FAP (familial adenomatous polyposis) patients (Kinzler et al., 1991) . Furthermore, these mutations are believed to be the initial step in the development of 80% of sporadic CRC cases (Fearon et al., 1990) .
Under physiological conditions, the APC protein, through its interactions with axin and glycogen synthase kinase (GSK)-3b regulates the cytoplasmic levels of b-catenin (Behrens et al., 1998; Barker et al., 2000) . This is a protein implicated in development (Barker et al., 2000) and tumorigenesis .
Mutation of the APC protein results in a truncated protein that is unable to bind to and to form a complex with axin, b-catenin and GSK3b Rowan et al., 2000) . As a result, GSK3b is unable to phosphorylate b-catenin. Phosphorylation of the latter is essential for its degradation by the ubiquitin-mediated proteasome pathway (Rubinfeld et al., 1996) . Consequently, stabilization of b-catenin is believed to parallel its translocation to the nucleus. Within the nucleus, b-catenin binds with the TCF-4 (Tcell factor) family of transcription factors resulting in the upregulation of genes that are believed to be involved in facilitating oncogenesis, such as cyclin D1 (Shtutman et al., 1999) and c-myc (He et al., 1998) . Both of these molecules have been demonstrated to be overexpressed in adenomatous polyps and CRC, and are believed to play pivotal roles in the regulation of the cell cycle. Other TCF-4 targets include PPARd, a nuclear receptor believed to be involved in colonic maturation/dierentiation (He et al., 1999; Mann et al., 1999) and matrilysin/MMP-7, a matrix metalloproteinase involved in regulating tumor cell invasion (Crawford et al., 1999) .
The integrin-linked kinase (ILK) is a recently identi®ed protein serine/threonine kinase, discovered through its interactions with the b1 integrin subunit using the yeast-two hybrid system (Hannigan et al., 1996) . ILK has been demonstrated to possess a number of oncogenic properties including: (a) induction of anchorage-independent cell cycle progression (Radeva et al., 1997) ; (b) inhibition of apoptosis ; (c) enhancement of tumorigenicity in nude mice (Wu et al., 1998) ; (d) enhancement of tumor cell invasion ; and (e) the stabilization of b-catenin and the enhancement of TCF-4-dependent gene transcription (Novak et al., 1998) .
Additionally, ILK has been demonstrated to phosphorylate protein kinase B (PKB) on Ser 473 and activate it in PTEN (phosphatase and tensin homologue deleted from Chromosome 10) mutant prostate cancer cells (Persad et al., 2000) as well as directly phosphorylate GSK3b and inhibit its activity (Delcommenne et al., 1998) . More recently, administration of a speci®c inhibitor of ILK (KP-SD1), or transfection with the kinase-dead version of ILK has been demonstrated to attenuate TCF-4-dependent transcription in colon cancer cell lines harboring APC mutations. Moreover, downregulation of transcription was accompanied by an increase in the levels of Ecadherin, a protein involved in regulating cell-to-cell contacts (Tan et al., 2001) . Downregulation of the latter is believed to facilitate the progression from the adenomatous to the cancer stage (Perl et al., 1998) . Furthermore, administration of KP-SD1, led to a signi®cant reduction in tumor growth in a xenograft mouse model (Tan et al., 2001) . Based upon these ®ndings, we hypothesized that dysregulation of ILK signaling may occur in adenomatous polyps.
Results and discussion
To address the question of ILK dysregulation, we speci®cally chose to examine the enzymatic activity and the protein expression of the ILK protein in polyps from patients diagnosed with FAP to ensure genetic homogeneity. Brie¯y, tissue homogenates corresponding to either the normal adjacent mucosa or the polyp lesion were subjected to speci®c ILK immunoprecipitation and immune complex kinase assays, using myelin basic protein (MBP) as a substrate. The data indicates that immunoprecipitated ILK exhibited a signi®cantly increased MBP phosphotransferase activity in the representative polyps that were analysed (Figure 1a ), when compared with their respective controls (P=0.002, for each data point, Student's t-test). A range of increase in enzyme activity above the control samples (40 ± 350%) was observed (n=10, data not shown). Three polyps did not show any increase in activity.
Although increased MBP phosphotransferase activity appeared to correlate with overexpression of the ILK protein in some of the samples that were analysed, this was not a linear correlation for the whole group. Importantly, increased expression of ILK protein was independent of changes in the expression of Erk1 and Erk2 within the same lesions ( Figure 1a ).
Next we wanted to determine whether ILK activity correlated with eects on downstream targets. For the representative patient sample (Figure 1b ), ILK activity not only correlated with overexpression of the protein, but also appeared to correlate with the stabilization of b-catenin expression. Strikingly, in support of the increased enzymatic activity of ILK, we found that GSK3b was signi®cantly phosphorylated on Ser9, indicative of its inhibition. Moreover, inhibition of GSK3b appeared to be independent of changes in its Four hundred mg of either the polyp or the appropriate adjacent control were subjected to a pre-clear step with a non-speci®c rabbit IgG antibody pre-absorbed to protein A sepharose for a 1 h at 48C. Samples were then centrifuged at 6000 r.p.m. and equal volumes of the supernatent were taken and incubated with 4 mg of the anti-ILK antibody overnight at 48C. Immunoprecipitates were subjected to an in vitro kinase assay using MBP as a substrate and resolved by autoradiography. A representative autoradiogram from one of the four assays is shown below the barchart. Lysates (30 mg) from each of the paired lesions were resolved by SDS ± PAGE and immunoblotted with the respective antibodies. Anti-ILK immunoblot, elevated MBP phosphotransferase activity correlated with overexpression of the ILK protein independent of changes in the levels of Erk1/2. (b) ILK activity and downstream targets. ILK activity is increased in the polyp compared with its respective control (representative autoradiogram). Anti-ILK immunoblot showing changes in ILK activity re¯ected overexpression of the ILK protein. Anti-b-catenin immunoblot, increased ILK activity correlated with the stablization of b-catenin expression. Anti-P-GSK3b immunoblot, ILK phosphotransferase activity correlated with the inhibition of GSK3b demonstrated by immunoblotting with the anti-Ser9 GSK3b antibody as well as by a decrease in the electrophoretic mobility using an anti-GSK3b antibody. Inhibition of the latter was independent of changes in its protein expression. The validity of these results was assessed by immunoblotting for CK2a and GAPDH. The levels of CK2a increased in the polyp samples when compared to the control (as previously described) while the levels of GAPDH were fairly consistent between all of the samples Figure 2 Overexpression of ILK in sporadic polyps. To delineate whether dysregulation of ILK signaling occurred in sporadic polyps we examined the expression of ILK by immunohistochemical analysis. All sections were incubated overnight at RT with the anti-ILK (1 : 100) antibody. Staining was completed according to Salh et al. (1999) . Representative cases are shown. (a ± c) Examination of ILK expression in sporadic polyps. The ILK protein is dramatically overexpressed in adenomatous crypts when compared to the control crypts. (d ± f) Three further representative cases exhibiting enhanced ILK immunostaining in the adenomatous crypts. (g) The staining intensity (weak=1, intermediate=2 and strong=3) was scored by three of us (AM, DO and BS) independently, and the results combined for all 10 pairs and statistical analysis performed using the Student's t-test (two-tailed). This shows a signi®cant dierence between the control and polyp samples (P50.001) expression. Based upon these ®ndings, we postulated that signals additional to a mutation of APC may be involved in polyp formation. These ®ndings are in agreement with a recent manuscript reporting a negative correlation between the loss of APC expression and a nuclear b-catenin signal in colorectal adenomas (lwamoto et al., 2000) . In that study, surprisingly, only 29% of the adenomatous polyps were negative for the APC protein, while 83% of the CRCs lost immunoreactivity, indicating that additional mechanisms such as the mutation of Axin or GSK3b may be involved earlier in the carcinogenic process. Perhaps, these additional inputs may work in concert with a loss of function of APC, promoting the translocation of b-catenin and facilitating disease progression. This hypothesis is corroborated by recent evidence indicating that administration of a small molecule ILK inhibitor KP-SD1, or transfection with a dominant-negative ILK, blocks TCF-4-dependent gene transcription (Tan et al., 2001) .
To address the speci®city of these results we speci®cally examined the expression of protein kinase casein kinase 2 (CK2) which has been previously reported to be overexpressed in colorectal adenomas (Munstermann et al., 1990) and GAPDH, a housekeeping gene. The results (Figure 1b) show that CK2 is overexpressed in these lesions and that similar protein levels were used in these studies, as shown by equivalent expression of the GAPDH protein.
To determine whether the dysregulation of ILK signaling observed in FAP patients also occurred in sporadic polyps, we analysed 10 sporadic polyps and adjacent control tissue by immunohistochemical analysis. The representative micrographs (Figure 2a ± f) demonstrate that ILK expression is strikingly increased in sporadic polyposis. It can be observed that the adenomatous crypts exhibit an intensely increased signal as compared with the normal crypts included within the same sample (Figure 2a ± c) . These impressive changes were apparent in all the lesions analysed, and were statistically signi®cant (P50.001).
It is widely recognized that NSAIDs play an important role in the incidence of CRC and this eect probably occurs at the stage of the aberrant crypt focus or polyp development (Reddy et al., 1996) . Furthermore sulindac has been demonstrated to regress polyps in FAP and suppress their growth in the Min mouse model of colon cancer (Labayle et al., 1991; BeazerBarclay et al., 1996) . However the precise targets involved in this process are unknown. As ILK is dysregulated at the polyp stage, we hypothesized that these agents may in¯uence ILK signaling and TCF-4 dependent transcription.
NSAIDs are believed to speci®cally inhibit prostaglandin (PG) biosynthesis. Liberated arachidonic acid is metabolized to PGs by both cyclooxygenase (Cox)-1 and 2. Cox-1 is constitutively expressed whereas the expression of Cox-2 is regulated by a number of stimuli including hypoxia and growth factor stimulation (Akashi et al., 2000) . More importantly, Cox-2 is overexpressed in both colorectal adenomas and CRC (Eberhart et al., 1994) , however its role in tumor growth was unclear until recently. Lewis lung carcinoma (LLC) cells were implanted into either wild-type, Cox-1 (7/7) or Cox-2 (7/7) mice to assess the eects of these molecules on tumor growth (Williams et al., 2000) . There was a signi®cant reduction in tumor growth in the Cox-2 (7/7) mice, whereas no dierences were evident in the other two groups. Furthermore, treatment of wild-type mouse ®broblasts with Celecoxib, a Cox-2 speci®c inhibitor, was Caco-2 cells were serum starved for 16 h and pre-treated with the appropriate concentration of the drug (ASA 5 mM and sulindac 1 mM) for an additional 2 h. Cells were then treated with 10% FBS for 10 min in either the presence or absence of the appropriate drug. ILK immunoprecipitation and immune complex kinase assays were performed as described in Figure 1 . A representative autoradiogram for one of the experiments is shown, as well as a Western blot to show equal protein loading. Administration of ASA (5 mM) resulted in a 68% inhibition of ILK activity (*P=0.02) while sulindac (1 mM) inhibited the activation by 87% (**P=0.001). (b) Inhibition of ILK is associated with an activation of GSK3b. Lysates from the same samples were immunoblotted with the antibody speci®c for serine 9 phosphorylated GSK3b. There was a signi®cant reduction in this signal with ASA and sulindac (#P=0.02). Similar ®ndings were evident in DLD-1 cells. Immunoblotting with the anti-GSK3b and GAPDH was performed to demonstrate equal protein loading associated with a reduction in vascular endothelial growth factor (VEGF) levels. These results indicate that Cox-2 may facilitate tumor growth through angiogenesis.
It is not clear whether inhibition of Cox-2 is sucient for eecting tumor regression, additional mechanisms may be required. In support of this, the following observations have been made: (a) NSAIDs induce apoptosis in cells lacking the detectable expression of Cox-2 (Chiu et al., 1997) ; (b) polyp regression in Min mice by sulindac is independent of eects on PG biosynthesis (Chiu et al., 1997) ; (c) exogenous addition of PGs in cells lacking the ability to synthesize PGs does not reverse the apoptotic eects of these agents (Hanif et al., 1996; Shi et al., 1995; Piazza et al., 1997) ; (d) sulindac sulfone, a metabolic metabolite of sulindac with no Cox-2 inhibitory properties promotes apoptosis (Piazza et al., 1995) . Furthermore, these agents have been shown to inhibit NFkB signaling (Yamamoto et al., 1999) , inhibit protein kinase B (PKB) (Hsu et al., 2000) , promote ceramide generation (Chan et al., 1998) , inhibit PPARd (He et al., 1999) and altered the Bax to Bcl-X L ratio (Zhang et al., 2000) . Taken together, these studies indicate that alternative NSAID targets exist, and understanding the mechanism of action of these drugs may aid in de®ning future therapy.
Overexpression of ILK has been demonstrated to not only in¯uence the distribution of b-catenin within the cell but has been demonstrated to upregulate TCF-4-dependent gene transcription, which is a prerequisite for the development of cancer (Roose et al., 1999) . More importantly, inhibition of ILK has been demonstrated to reverse the eects on TCF-4-dependent gene transcription independently of mutations in APC (Tan et al., 2001) . Therefore, it is plausible that NSAIDs may inhibit ILK signaling and inhibition of this signaling nexus may in¯uence polyp regression. To explore this further, modulation of signaling by these agents was carried out in a similar fashion to Yamamoto et al. (1999) , with minor modi®cations. Brie¯y, Caco-2 cells were pre-treated with either ASA (5 mM) or sulindac (1 mM), and then stimulated with serum for 10 min. The results ( Figure  3a ) indicate that these agents signi®cantly inhibit the activation of ILK in vivo. Administration of sulindac (1 mM) resulted in an impressive 87% inhibition of ILK activity whereas ASA (5 mM) resulted in a 68% reduction, respectively. Both of these eects were statistically signi®cant. Similar results were observed in DLD-1 cells (data not shown). Furthermore, these changes were reproducible using ®bronectin as the activating stimulus (data not shown). To corroborate these ®ndings, we speci®cally examined the phosphorylation status of GSK3b, since ILK is known to regulate phosphorylation of GSK3 on the Ser9 position. Inhibition of ILK by NSAIDs resulted in a signi®cant decrease in the phosphorylation of Ser9, consistent with its activation (Figure 3b) . Expression of GSK3b and GAPDH demonstrate equal protein loading.
Overexpression of ILK has not only been demonstrated to inhibit GSK3b but has been previously reported to enhance TCF-4-dependent gene transcription. Furthermore, administration of KP-SD1, a selective ILK inhibitor, has been demonstrated to not only reverse this eect on transcription but to upregulate the expression of E-cadherin, a mediator of cell-to-cell interactions (Tan et al., 2001) . Based upon this data, together with the observed inhibition of ILK by sulindac, we postulated that NSAIDs might inhibit TCF-4-dependent gene transcription. To address this, we used a transient transfection reporter assay to measure TCF-4-dependent transcription Morin et al., 1997) . The data (Figure 4a) indicates that a 24 h treatment with NSAIDs leads to a downregulation of TCF-4-dependent gene transcription. Speci®cally, sulindac (1 mM) reduced transcription by 61% while ASA (5 mM) resulted in a 40% decrease. Similar results were observed in DLD-1 and SW 480 cells (data not shown). The accompanying Renilla (control reporter plasmid) data indicates that the observed eects are speci®c for TCF-4.
To con®rm the eects of NSAIDs on TCF-4-dependent transcription, we chose to examine the protein expression levels of cyclin D1, a target of ILK (D'Amico et al., 2000; Tan et al., 2001) . The data (Figure 4b ) indicates a dose-dependent eect on cyclin D1 downregulation upon treatment with either drug for 24 h. Expression of GAPDH demonstrates equal protein loading.
Several lines of evidence indicate that treatment with NSAIDs results in the induction of apoptosis (Piazza et al., 1995; Hanif et al., 1996; Chan et al., 1998) . To demonstrate that these agents block TCF-4-dependent gene transcription in the cell lines we tested, independently of apoptosis, we measured the percentage of viable cells using the MTS assay, after 24 h of drug exposure to mirror our transcriptional studies in three dierent cell lines, Caco-2, DLD-1 and HCT-116 cells. Administration of ASA (1 mM) had no appreciable eects on viability in either the Caco-2 or DLD-1 cells, but resulted in a signi®cant decrease in cyclin D1 levels (Figure 4b,c) . Conversely, 500 mM ASA resulted in a 44% reduction in viability in HCT-116 cells, a cell line known to express wild-type p53 (O'Connor et al., 1997) and Bax (Zhang et al., 2000) . Similarly, exposure to sulindac (500 mM) resulted in minimal changes in the viability of Caco-2 cells (8% reduction) and DLD-1 cells (no change), but resulted in a signi®cant decrease in the levels of cyclin D1 (Figure 4b,c) . Notably, the HCT-116 cell line appeared to be extremely sensitive to sulindac at this concentration demonstrating a 46% reduction in cell viability. These dierential eects on cell viability are in agreement with a recent paper that tested the sensitivity of these agents on a number of colonic cell lines (Akashi et al., 2000) . Overall, these results provide the ®rst incontrovertible evidence that sulindac eects TCF-4 transcriptional downregulation and cyclin D1 expression prior to eects on cell viability. Down-regulation of cyclin D1 may be Following transfection, Caco-2 cells were placed in 1% FBS/M199 in the presence or absence of the appropriate drug (ASA 5 mM and sulindac 1 mM) for 24 h. Cells were harvested and assayed for transcriptional activity with a luminometer. Data are expressed as relative light units (RLU). All experiments were done in triplicate on at least three independent occasions. ASA inhibited TCF-4 transcriptional activity by 40% while sulindac reduced it by 61%. Similar eects were observed in DLD1 and SW480 cells. (probability *P50.01, **P50.001) (b) Administration of NSAIDs leads to a down-regulation of cyclin D1 expression in a dosedependent fashion. Caco-2 cells were incubated in the presence of varying dosages of either ASA (50 mM to 5 mM) or sulindac (100 mM to 1 mM) for 24 h. The results demonstrated that administration of either ASA or sulindac lead to a downregulation of cyclin D1 expression. (c) Transcriptional eects are independent of eects on cell viability. To demonstrate that downregulation of cyclin D1 were independent of eects on cell viability we utilized the MTS formazan method. 10 ml/well of MTS/PMS solution was added to 100 ml of culture medium in 96 well plates 1 h prior to terminating the experiment in a humidi®ed chamber at 378C, 5% CO 2 . The absorbance was measured at 490 nm using an Elisa plate reader. Results are represented as per cent change over the control. Similar results were obtained on at least three independent occasions associated with a higher percentage of cells arrested at the G 0 /G 1 phase of the cell cycle, in keeping with recent ®ndings (Akashi et al., 2000) . This cell cycle arrest may be involved in the subsequent induction of apoptosis.
In summary, we have shown for the very ®rst time that ILK, a protein kinase that when overexpressed, is known to have similar consequences to overexpression of b-catenin, is hyperexpressed and shows enhanced MBP phosphotransferase activity in FAP patients. We also report an impressively increased ILK protein expression in colonic adenomatous crypts of patients with sporadic polyps (100%). Additionally, we provide novel evidence that sulindac may target ILK and ILKmediated functions such as the inhibition of GSK3b and the activation of TCF-4-dependent gene transcription. In conclusion, we propose that intervention with a selective ILK inhibitor could prove to be an eective modality in the treatment of FAP, or sporadic polyposis, with possible rami®cations for chemoprevention of colorectal cancer.
